v3.25.4
ACQUISITIONS AND LICENSING AGREEMENTS (Tables)
 12 Months Ended
Dec. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of fair values of assets acquired and liabilities assumed The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date:
(in millions)
Property, plant and equipment, net$7 
Intangible assets, net1 
Total identifiable assets8 
Goodwill67 
Total fair value of consideration transferred$75 
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of Elios Vision, as of the acquisition date:
(in millions)
Intangible assets, net$177 
Trade receivables, net2 
Inventories, net4 
Property, plant and equipment, net7 
Other non-current assets1 
Accrued and other current liabilities(7)
Other non-current liabilities(23)
Total identifiable net assets161 
Goodwill27 
Total fair value of consideration transferred$188 
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the XIIDRA Acquisition as of the acquisition date, inclusive of measurement period adjustments:
(in millions)
Intangible assets, net$1,600 
Prepaid expenses and other current assets162 
Accrued and other current liabilities(1)
Other non-current liabilities(31)
Total identifiable net assets1,730 
Goodwill23 
Total fair value of consideration transferred$1,753 
Schedule of aggregate acquisition consideration The total aggregate acquisition consideration was approximately $188 million and is calculated as follows:
(in millions)
Cash consideration paid$99 
Estimated fair value of contingent consideration89 
Aggregate purchase consideration$188 
The estimated aggregate acquisition consideration of approximately $1,753 million is calculated as follows:
(in millions)
Cash consideration paid to Novartis at closing, per Acquisition Agreement$1,750 
Estimated fair value of contingent consideration3 
Aggregate purchase consideration$1,753 
Schedule of intangible assets acquired, business combination The intangible assets acquired related to the acquisition of Elios Vision, as well as their fair values and estimated useful life consist of the following:
(in millions)Fair ValueEstimated Useful Life
(In Years)
Acquired in-process research and development intangible asset$95 N/A
Product brands
63 13
Corporate brands
17 10
Other2 9
Total Intangible assets, net$177 
The intangible assets acquired related to the acquisition of Trukera Medical, as well as their fair values and estimated useful life consist of the following:
(in millions)Fair ValueEstimated Useful Life
(In Years)
Product brand
$14 10
Customer relationships2 7
Total Intangible assets, net$16 
The intangible assets acquired, as well as their fair values and estimated useful life consist of the following:
(in millions)Fair ValueEstimated Useful Life
(In Years)
Product brand
$1,595 8.75
Acquired in-process research and development intangible asset5 N/A
Total Intangible assets, net$1,600 
Schedule of pro forma information
The following table presents the unaudited pro forma combined results of the Company and the acquired assets for the year ended December 31, 2023, as if the XIIDRA Acquisition, and the related financing, had occurred on January 1, 2022:
(in millions)2023
Revenues$4,395 
Net loss attributable to Bausch + Lomb Corporation$(471)
Schedule of intangible assets acquired, asset acquisition The intangible assets acquired, as well as their estimated useful lives consist of the following:
(in millions)Estimated Useful Life
(In Years)
Corporate brands
$73 12
Product brands12 10
Technology and other6 9
Total Intangible assets, net$91